Nuformix

Nuformix is a pharmaceutical development company using proprietary cocrystal technology to repurpose existing drugs for unmet medical needs in fibrosis and oncology.

By reengineering a drug's crystal form, the company improves properties such as dissolution and absorption, creating differentiated, patentable products at lower cost and risk than developing new medicines.

Its pipeline includes a Phase 1 asset for chemotherapy-induced nausea and vomiting, a preclinical inhaled treatment for idiopathic pulmonary fibrosis, and an early-stage oncology candidate.